Positive Effect on MS With Treatment of Metabolic Syndrome
In this study, 20 patients receiving metformin hydrochloride and 10 receiving pioglitazone hydrochloride had significantly fewer new or enlarging T2 lesions or gadolinium-enhancing lesions confirmed by brain magnetic resonance imaging after about 2 years of treatment compared with a control group of 20 patients with MS and metabolic syndrome who did not receive metformin or pioglitazone.
Source: JAMA Neurology - Category: Neurology Source Type: research
More News: Actoplus MET | Actos | Brain | Eating Disorders & Weight Management | Fortamet | Metabolic Syndrome | Metformin | MRI Scan | Multiple Sclerosis | Neurology | Obesity | Study